NEWS: We just announced we're acquiring Mavupharma to strengthen our #immunooncology early pipeline. Learn more: https://t.co/cUXZZzK1ln $ABBV #oncology#IO
As @MavuPharma is showing, routes to delivery matter. Orally available non-nucleotide therapies like their MAVU-104 could be transformative for the space and patients. #CIM19 2/2 https://t.co/CNaC3RZ5cl
Stephen Burley: “Of the 210 new drugs approved between 2010 and 2016, 184 were informed by structural biology. “ That’s 88%.
Vast majority of these were from X-ray crystallography. Hug a structural biologist, people. Hug a structural biologist.
Not 1, not 2, but 3 papers in @nature this week by James Chen @UTSWNews, including the surprising finding tht "induction of autophagy is a primordial function of the cGAS–STING pathway"
https://t.co/kjSzN8taLa
https://t.co/jUsNZPOVI8 …
https://t.co/zqBHkVe83I …
We're pleased to have our lead program discussed in this terrific overview of #STING pathway drug development in the latest @NatureBiotech!
https://t.co/1mDubsUBUd